MD Anderson Cancer Center
MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston on the Texas Medical Center campus.

MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 41 National Cancer Institute-designated comprehensive cancer centers today.

U.S. News & World Report’s “Best Hospitals” survey ranked MD Anderson as the top hospital in the nation for cancer care in 2013. It has achieved this highest ranking 10 times in the past 12 years.

Patient Care

Since 1944, more than 900,000 patients have turned to MD Anderson for cancer care. The multidisciplinary approach to treating cancer was pioneered at MD Anderson. This approach brings together teams of experts across disciplines to collaborate on the best treatment plan for patients. And because MD Anderson’s experts focus solely on cancer, they’re renowned for treating all types of cancer, including rare or uncommon diseases.

In Fiscal Year 2012, MD Anderson’s 20,000 cancer fighters provided care for more than 115,000 patients. Of those, nearly one-third were new patients. About one-third of patients come to Houston from outside Texas, seeking the knowledge-based care that has made MD Anderson so widely respected. There were about 8,500 registrants on clinical trials exploring novel therapies and diagnostic tests in FY12, making it the largest such program in the nation.

The Institute for Cancer Care Innovation is helping MD Anderson lead the way in developing an improved cancer-care model through studies that determine the best methods to deliver care that’s safe, timely, efficient, effective, equitable and patient-centered.

The institution is accredited by The Joint Commission, an organization that ensures patients receive the best and safest health care possible. MD Anderson’s radiation oncology practice is accredited by the American College of Radiology and the American Society for Therapeutic Radiology and Oncology. The institution also holds Magnet Nursing Services Recognition status from the American Nurses Credentialing Center.


At MD Anderson, important scientific knowledge gained in the laboratory is rapidly translated to clinical care. In FY12, MD Anderson invested more than $647 million in research, an increase of 33% in the past five years. The institution ranks first in the number of research grants awarded and total amount of grant funds given by the NCI and holds 12 NCI Specialized Programs of Research Excellence (SPORE) grants.

An unprecedented Moon Shots Program was launched last year to dramatically accelerate the pace of converting scientific discoveries into clinical advances that significantly reduce cancer deaths. The program brings together teams of researchers and clinicians to mount comprehensive attacks on eight cancers initially. They work as part of six moon shot teams: acute myeloid leukemia and myelodysplastic syndrome, chronic lymphocytic leukemia, melanoma, lung cancer, prostate cancer, and triple-negative breast and high-grade serous ovarian cancers, which are linked at the molecular level. The goal is for all cancers to become moon shots.

Creation of the Institute for Applied Cancer Science has expanded MD Anderson’s research endeavors. The institute identifies and validates new cancer targets, converts the scientific knowledge into new cancer drugs, and advances the novel agents into innovative clinical trials through a streamlined collaboration between academic medicine and the biotechnology industry.

The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy is an international center of clinical excellence focusing on using the latest advances in genetic information to develop safe, more effective treatments for patients on a case-by-case basis.

The Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer comprises seven translational research centers focused on genomics, proteomics, screening, diagnostic imaging and drug development.

In MD Anderson’s Institute for Basic Science, researchers work to better understand the makeup of healthy human cells, how they function under normal conditions and what happens when cancer develops. This knowledge feeds directly into clinical research, prevention, diagnosis and treatment.


MD Anderson continues to set the standard in cancer prevention research and the translation of new knowledge into innovative, multidisciplinary care for patients, survivors and people at average or elevated risk for developing cancer.

The institution’s Cancer Prevention and Population Sciences is dedicated to eradicating cancer through pioneering research into the roles played by biologic, genetic, environmental, behavioral and social factors in cancer development, as well as investigations of behavioral, surgical, medical and social interventions to prevent or reduce cancer risk.

Through the Duncan Family Institute for Cancer Prevention and Risk Assessment, investments are being made in promising new research directions and basic research and clinical studies are being integrated to accelerate their translation from the clinic to the community.

The new Health Services Research department is focused on studying health care costs, quality and access, and seeking ways to improve health care delivery, safety, availability and affordability.

The Cancer Prevention Center provides cancer-risk assessments, screening exams based on genetics, age and gender, and personalized risk-reduction strategies, including chemoprevention.


With employees working in more than 50 buildings in the greater Houston area and in central Texas, MD Anderson is the largest freestanding cancer center in the world. Its facilities in the Texas Medical Center — the largest medical center in the world — cover more than 14 million square feet and feature the latest equipment and facilities to support growing needs in outpatient and inpatient care, research, prevention and education.

The Sheikh Zayed Bin Sultan Al Nahyan Building for Personalized Cancer Care is under construction. The 12-floor, 615,000-square-foot facility is scheduled to be completed in August 2014.

In addition to MD Anderson’s TMC campus, four regional care centers in the greater Houston area (Bay Area, Katy, Sugar Land, The Woodlands) and two research campuses in Bastrop County, Texas, the institution has developed a network of national and international relationships.

MD Anderson Cancer Network™

Partner members

Banner MD Anderson Cancer Center (Gilbert, Ariz.)

MD Anderson Cancer Center at Cooper (Camden, NJ)

Certified members

Nine health systems and hospitals in eight states

MD Anderson affiliates

MD Anderson Cancer Center Madrid (Madrid, Spain)

MD Anderson Radiation Treatment Center at Presbyterian Kaseman Hospital (Albuquerque, N.M.)

MD Anderson Radiation Treatment Center at American Hospital (Istanbul, Turkey)

Sister institutions

Academic collaborations with 27 sister institutions in 20 countries.

For more information about MD Anderson, visit or call 877-632-6789.